EASH Dressing on Chronic Venous Leg Ulcers
This study has been completed.
Sponsor:
ConvaTec Inc.
Information provided by (Responsible Party):
ConvaTec Inc.
ClinicalTrials.gov Identifier:
NCT01497210
First received: December 20, 2011
Last updated: April 24, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to evaluate the safety and preliminary performance of EASH dressing for 4 weeks followed by AQUACEL® dressing for 4 weeks on venous leg ulcers.
| Condition | Intervention | Phase |
|---|---|---|
|
Leg Ulcer |
Device: EASH dressing |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Multi-centre, Non-comparative Study to Evaluate the Safety and Preliminary Performance of the EASH Dressing on Chronic Venous Leg Ulcers |
Resource links provided by NLM:
Further study details as provided by ConvaTec Inc.:
Primary Outcome Measures:
- Safety [ Time Frame: All 8 weeks ] [ Designated as safety issue: No ]Nature and frequency of adverse events.
Secondary Outcome Measures:
- Ulcer Improvement (wound bed) [ Time Frame: Baseline, week 4 and week 8 ] [ Designated as safety issue: No ]
- Ulcer Improvement (peri-ulcer) [ Time Frame: Baseline, week 4 and week 8 or final visit ] [ Designated as safety issue: No ]
- Healing [ Time Frame: Weekly for 4 weeks then biweekly for 4 weeks or final visit ] [ Designated as safety issue: No ]Reduction in ulcer area
- Healing [ Time Frame: 8 weeks or final visit ] [ Designated as safety issue: No ]Number of subjects healed
- Healing [ Time Frame: 8 weeks or final visit ] [ Designated as safety issue: No ]Time to healing
- Ulcer pain [ Time Frame: Weekly for 4 weeks then biweekly for 4 weeks or final visit ] [ Designated as safety issue: No ]
- Comfort [ Time Frame: Weekly for 4 weeks then biweekly for 4 weeks ] [ Designated as safety issue: No ]
- Ease of use [ Time Frame: Weekly for 4 weeks then biweekly for 4 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 40 |
| Study Start Date: | November 2011 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: EASH |
Device: EASH dressing
Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects over 18 years, willing and able to provide written informed consent.
- Subjects who have an ankle to brachial pressure index (ABPI) of 0.8 or greater
- Subjects who have a venous leg ulcer (i.e. CEAP classification of C6 1), with duration less than 24 months and size ranging between 5 cm2-40 cm2.
- Subjects' leg ulcers will meet at least 3 of the 5 following clinical signs of infection: pain between two dressing changes, peri-ulcer skin erythema/inflammation, oedema, malodour (foul odour), and heavy exudate.
- Subjects who agree to wear compression therapy daily in combination with the trial dressing.
Exclusion Criteria:
- Subjects with a history of skin sensitivity to any of the components of the study product.
- Subjects who have had current local or systemic antibiotics in the week prior to inclusion with the exception of wounds that are considered to be clinically infected at baseline.
- Subjects whose leg ulcers are malignant, or who have had recent deep venous thrombosis or venous surgery within the last 3 months.
- Subjects who have progressive neoplastic lesion treated by radiotherapy or chemotherapy, or on-going treatment with immunosuppressive agents
- Subjects exhibiting any other medical condition which, according to the Investigator, justifies the subject's exclusion from the study
- Subjects who have participated in a clinical study within the past month.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01497210
Locations
| Poland | |
| Mikomed | |
| Lodz, Poland | |
| Cross Medica | |
| Warszawa, Poland | |
| Medservice | |
| Zabrze, Poland | |
| United Kingdom | |
| Wound Healing Research Unit | |
| Heath Park, Cardiff, United Kingdom, CF14 4XN | |
| Axbridge & Wedmore Medical Practice | |
| Axbridge, Somerset, United Kingdom, BS26 2BJ | |
| Arrowe Park Hospital | |
| Upton, Wirral, United Kingdom, CH49 5PE | |
Sponsors and Collaborators
ConvaTec Inc.
Investigators
| Principal Investigator: | Keith Harding | Wound Healing Research Unit, Cardiff University |
More Information
No publications provided
| Responsible Party: | ConvaTec Inc. |
| ClinicalTrials.gov Identifier: | NCT01497210 History of Changes |
| Other Study ID Numbers: | CW-0205-11-U356 |
| Study First Received: | December 20, 2011 |
| Last Updated: | April 24, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency Poland: Ethics Committee Poland: Ministry of Health |
Additional relevant MeSH terms:
|
Leg Ulcer Ulcer Varicose Ulcer Skin Ulcer Skin Diseases |
Pathologic Processes Varicose Veins Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on June 17, 2013